Stay updated on CIN-107 in Primary Aldosteronism Clinical Trial
Sign up to get notified when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.
Latest updates to the CIN-107 in Primary Aldosteronism Clinical Trial page
- Check5 days agoChange DetectedResults were posted for CIN-107 in adults with primary aldosteronism, including treatment-emergent adverse events, 12-week SBP/DBP changes, BP response rates, and pharmacodynamic marker responses (Part 1). Previously listed safety and efficacy data elements were removed from the page.SummaryDifference3%
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded Revision: v3.4.2; removed the funding/operating-status notice and the previous Revision: v3.4.1.SummaryDifference0.4%
- Check33 days agoChange DetectedAdded a government funding notice about potential delays and status updates, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%
- Check40 days agoChange DetectedNew UI element 'Show glossary' and a v3.4.0 metadata revision with adjusted QC criteria labeling and FEAR Act data visibility have been introduced. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check54 days agoChange DetectedNew revision entry v3.3.4 was added and the previous entry v3.3.3 was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check76 days agoChange DetectedA centralized Locations section was added listing sites in CA, IL, MD, MI, MN, OH, and TX, and the prior state-specific location sections were removed.SummaryDifference0.9%
Stay in the know with updates to CIN-107 in Primary Aldosteronism Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.